Weekly Digest – May 2026 Weekly Digest – May 2026 15 May 2026: ENHERTU approved in the US for two new indications for patients with HER2-positive early Breast cancer ENHERTU received two new U.S. FDA approvals in HER2-positive early breast […]
Weekly Digest – May 2026 Weekly Digest – May 2026 21 May 2026: CDSCO approves Astellas’ PADCEV for first-line advanced Bladder cancer treatment Astellas Pharma’s PADCEV has been approved by CDSCO for first-line treatment of locally advanced or metastatic urothelial […]
Weekly Digest – May 2026 Weekly Digest – May 2026 22 May 2026: PADCEV in combination with Keytruda receives positive CHMP opinion for the treatment of patients with resectable MIBC who are ineligible for cisplatin-based chemotherapy Astellas Pharma announced that […]
Weekly Digest – May 2026 Weekly Digest – May 2026 18 May 2026: TroFuse-005 trial evaluating Sacituzumab Tirumotecan met primary endpoints of OS and PFS in certain patients with advanced or recurrent Endometrial cancer Merck & Co. announced that the […]
Weekly Digest – May 2026 Weekly Digest – May 2026 19 May 2026: Hengrui announces phase 3 trial of HER3 ADC SHR-A2009 for EGFR-mutant advanced NSCLC met primary endpoint of PFS Jiangsu Hengrui Pharmaceuticals announced that its HER3-directed ADC SHR-A2009 […]
Weekly Digest – May 2026 Weekly Digest – May 2026 21 May 2026: Kelun-Biotech announces phase 3 trial of Sacituzumab Tirumotecan versus Chemotherapy as 1L treatment for advanced TNBC met primary endpoint of PFS Sichuan Kelun-Biotech Biopharmaceutical announced that the […]
